8 research outputs found
p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome
KIT and RAS signalling pathways in testicular germ cell tumours: new data and a review of the literature
Lung resistance-related protein (LRP) predicts favorable therapeutic outcome in Acute Myeloid Leukemia
Amphicrine carcinoma of the stomach and intestine: a clinicopathologic and pan-cancer transcriptome analysis of a distinct entity
Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
No biological molecule in the field of oncology has been more extensively or more successfully targeted for therapeutic intent than the product of the c-erbB2 gene, HER2/neu. This is the second of a comprehensive three-part review of the foundation for and therapeutic targeting of HER2/neu. The distribution of HER2/neu overexpression and/or gene amplification by individual tumor sites and histologies will be comprehensively surveyed and described. This provides a bridge between the primarily basic science focused Part I, and the survey of clinical applications to follow in Part III. In combination, this comprehensive survey will identify opportunities and promising areas for future evaluation of HER2/neu-targeted therapies, highlighting the importance of HER2/neu as an increasingly important therapeutic target